HCV SPECIALIST STUDY GUIDE 2025/2026 QUESTIONS
WITH SOLUTIONS RATED A+
✔✔Serologic Assay - ✔✔(HCV)
Screening modality that detects anti-HCV antibodies
- Cannot different between acute, chronic, or past
- False (-) if testing during *first 8 weeks or immunosuppression*
- False (+) cross-reactivity with other viral antigens
✔✔PCR - ✔✔(HCV)
Screening modality that assesses for serum HCV RNA (viral load)
- Confirms acute vs chronic
- Can detect virus 1-2 weeks after exposure
- Used to monitor Tx response
- *Does not correlate w/ disease severity/progress*
✔✔HBV - ✔✔(HCV)
Before initiating Tx with DAAs, ALL patients should be tested for ________
- DAAs may cause reactivation
✔✔Mavyret - ✔✔(HCV)
DAAs
*Glecaprevir (100mg) + Pibrentasvir (40mg)*
1) Tx naive genotype 1-6 HCV +/- compensated cirrhosis
- 3T PO QD x 8 weeks (12 for compensated cirrhosis)
2) Genotype 1 HCV failed previous NS5A +/- compensated cirrhosis
- 3T PO QD x 16 weeks
3) Genotype 1 HCV failed NS3/4A inhibitor +/- compensated cirrhosis
- 3T PO QD x 12 weeks
✔✔8, 12, 16, 12 - ✔✔(HCV)
DAAs
MAVYRET (Glecaprevir + Pibrentasvir)
,ALL INDICATIONS are dosed at *3 tablets PO QD* for a duration of:
1) Tx Naive genotype 1-6 HCV ______ weeks
_____ weeks for +CC
2) Genotype 1 HCV failed HS5A +/- CC ______ weeks
3) Genotype 1 HCV failed HS3/4A +/0 CC
______ weeks
✔✔3A4 Inducers - ✔✔(HCV)
DAAs
MAVYRET (Glecaprevir + Pibrentasvir)
DDIs with concomitant ________ NOT recommended
- May cause drug failure
✔✔Harvoni - ✔✔(HCV)
DAAs
*Ledipasvir (90mg) + Sofosbuvir (400mg)*
1) Genotype 1 HCV
- Tx naive +/- CC
- Tx experienced
- Decompensated cirrhosis
- Post liver txp
2) Genotype 4 HCV
- Tx naive or experienced
- Post liver txp
3) Genotype 5-6 HCV
✔✔1, 4, 5, 6 - ✔✔(HCV)
DAAs
HARVONI (Ledipasvir + Sofosbuvir)
Is indicated to Tx (4) genotypes of HCV
, ✔✔12, 24 - ✔✔(HCV)
DAAs
HARVONI (Ledipasvir + Sofosbuvir)
*1T PO QD for all regimens*
For Tx of ALL genotypes and situations, duration of Tx is for ______ weeks
EXCEPT for *Tx-experienced GENOTYPE 1 patients WITH CC*, then duration is
______ weeks
✔✔Ribavirin - ✔✔(HCV)
DAAs
HARVONI (Ledipasvir + Sofosbuvir)
For instances of decompensated cirrhosis or liver transplant REGARDLESS of HCV
genotype, Harvoni is given *in combination* with weight-based ________
✔✔PgP Inducers - ✔✔(HCV)
DAAs
HARVONI (Ledipasvir + Sofosbuvir)
Experiences DDIs with ______ (since both components are substrates)
- Concurrent admin can result in Tx failure
✔✔H2RAs/PPIs/Antacids, Amiodarone, Digoxin, Rosuvastatin - ✔✔(HCV)
DAAs
HARVONI (Ledipasvir + Sofosbuvir)
Experiences DDIs:
1) With (3) agents resulting in decreased Harvoni absorption
2) With ______: severe bradycardia
3) With ______: digoxin toxicity
WITH SOLUTIONS RATED A+
✔✔Serologic Assay - ✔✔(HCV)
Screening modality that detects anti-HCV antibodies
- Cannot different between acute, chronic, or past
- False (-) if testing during *first 8 weeks or immunosuppression*
- False (+) cross-reactivity with other viral antigens
✔✔PCR - ✔✔(HCV)
Screening modality that assesses for serum HCV RNA (viral load)
- Confirms acute vs chronic
- Can detect virus 1-2 weeks after exposure
- Used to monitor Tx response
- *Does not correlate w/ disease severity/progress*
✔✔HBV - ✔✔(HCV)
Before initiating Tx with DAAs, ALL patients should be tested for ________
- DAAs may cause reactivation
✔✔Mavyret - ✔✔(HCV)
DAAs
*Glecaprevir (100mg) + Pibrentasvir (40mg)*
1) Tx naive genotype 1-6 HCV +/- compensated cirrhosis
- 3T PO QD x 8 weeks (12 for compensated cirrhosis)
2) Genotype 1 HCV failed previous NS5A +/- compensated cirrhosis
- 3T PO QD x 16 weeks
3) Genotype 1 HCV failed NS3/4A inhibitor +/- compensated cirrhosis
- 3T PO QD x 12 weeks
✔✔8, 12, 16, 12 - ✔✔(HCV)
DAAs
MAVYRET (Glecaprevir + Pibrentasvir)
,ALL INDICATIONS are dosed at *3 tablets PO QD* for a duration of:
1) Tx Naive genotype 1-6 HCV ______ weeks
_____ weeks for +CC
2) Genotype 1 HCV failed HS5A +/- CC ______ weeks
3) Genotype 1 HCV failed HS3/4A +/0 CC
______ weeks
✔✔3A4 Inducers - ✔✔(HCV)
DAAs
MAVYRET (Glecaprevir + Pibrentasvir)
DDIs with concomitant ________ NOT recommended
- May cause drug failure
✔✔Harvoni - ✔✔(HCV)
DAAs
*Ledipasvir (90mg) + Sofosbuvir (400mg)*
1) Genotype 1 HCV
- Tx naive +/- CC
- Tx experienced
- Decompensated cirrhosis
- Post liver txp
2) Genotype 4 HCV
- Tx naive or experienced
- Post liver txp
3) Genotype 5-6 HCV
✔✔1, 4, 5, 6 - ✔✔(HCV)
DAAs
HARVONI (Ledipasvir + Sofosbuvir)
Is indicated to Tx (4) genotypes of HCV
, ✔✔12, 24 - ✔✔(HCV)
DAAs
HARVONI (Ledipasvir + Sofosbuvir)
*1T PO QD for all regimens*
For Tx of ALL genotypes and situations, duration of Tx is for ______ weeks
EXCEPT for *Tx-experienced GENOTYPE 1 patients WITH CC*, then duration is
______ weeks
✔✔Ribavirin - ✔✔(HCV)
DAAs
HARVONI (Ledipasvir + Sofosbuvir)
For instances of decompensated cirrhosis or liver transplant REGARDLESS of HCV
genotype, Harvoni is given *in combination* with weight-based ________
✔✔PgP Inducers - ✔✔(HCV)
DAAs
HARVONI (Ledipasvir + Sofosbuvir)
Experiences DDIs with ______ (since both components are substrates)
- Concurrent admin can result in Tx failure
✔✔H2RAs/PPIs/Antacids, Amiodarone, Digoxin, Rosuvastatin - ✔✔(HCV)
DAAs
HARVONI (Ledipasvir + Sofosbuvir)
Experiences DDIs:
1) With (3) agents resulting in decreased Harvoni absorption
2) With ______: severe bradycardia
3) With ______: digoxin toxicity
